Eribulin mesylate Injection

About Eribulin mesylate Injection

Eribulin is a chemotherapy drug.  It's a treatment for breast cancer and liposarcoma that has: spread to surrounding tissue (locally advanced cancer) spread to other areas of the body (metastatic or advanced cancer)

• Generic (Eribulin mesylate) sold as brand name 博立宁® in china.

Breast Cancer, Metastatic

Indicated for metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease; prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting

1.4 mg/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle  

Liposarcoma

Indicated for unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen

1.4 mg/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle  

Dosage Modifications

Assess for peripheral neuropathy and obtain CBC counts prior to each dose

Recommended dose delays

• Do not administer on Day 1 or Day 8 for any of the following

  • ANC <1,000/mm³
  • Platelets <75,000/mm³
  • Grade 3 or 4 nonhematological toxicities

• The Day 8 dose may be delayed for a maximum of 1 week:

  • If toxicities do not resolve or improve to ≤Grade 2 severity by Day 15, omit the dose
  • If toxicities resolve or improved to ≤Grade 2 severity by Day 15, administer at a reduced dose and initiate the next cycle no sooner than 2 weeks later

Recommended dose reductions

• If a dose has been delayed for toxicity and then recovered to ≤Grade 2 severity, resume at reduced doses (see below)
• Do not re-escalate once dose has been reduced

• Permanently reduce the 1.4 mg/m² dose to 1.1 mg/m² for any of the following:

  • ANC <500/mm³ for >7 days
  • ANC <1,000/mm³ with fever or infection
  • Platelets <25,000/mm³
  • Platelets <50,000/mm³ requiring transfusion
  • Nonhematologic Grade 3 or 4 toxicities
  • Omission or delay of Day 8 dose in previous cycle for toxicity

• Permanently reduce dose to 0.7 mg/m² for any of the following:

  • Occurrence of any event requiring permanent dose reduction while receiving 1.1 mg/m²

• Discontinue

  • Occurrence of any event requiring permanent dose reduction while receiving 0.7 mg/m²

Renal impairment

• Moderate-to-severe (CrCl 15-49 mL/min): 1.1 mg/m² IV

Hepatic impairment

• Mild (Child-Pugh A): 1.1 mg/m² IV
• Moderate (Child-Pugh B): 0.7 mg/m² IV